Initiated Outperform X

OABI OmniAb

RBC Capital Mkts

$6

Initiated Buy X

OABI OmniAb

The Benchmark Company

$8

Initiated Buy X

OABI OmniAb

Craig Hallum

$10

Initiated Outperform X

OABI OmniAb

Cowen

$10

Initiated Buy X

OABI OmniAb

H.C. Wainwright

$11

Initiated Buy X

OABI OmniAb

Truist

$10

Initiated Outperform X

OABI OmniAb

Credit Suisse

$13

Initiated Outperform X

OABI OmniAb

SVB Leerink

$6

Initiated Buy X

OABI OmniAb

Stifel

$12

OABI  OmniAb, Inc.

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.